Patent · US Active

Crystal modifications of elobixibat

US10519120B2 · kind B2 · utility

0Cited by

34References

37Claims

0Family size

Assignee

ELOBIX AB · SE

Inventors

Ingvar Ymen · Boo, SE
Martin Bohlin · Stockholm, SE
Thomas Larsson · Luleå, SE
Helena Nicklasson · Malmö, SE

Key dates

Filing date	Dec 27, 2018
Grant date	Dec 31, 2019
Priority date	—
Expiry date	Dec 27, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to crystal modifications of N-{(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl]oxy}acetyl)amino]-2-phenylethanolyl}glycine (elobixibat).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.